News Flash – Noticia de última Hora 

October, 20, 2022 | 8 Comments


  1. ‘Likewise, it reports that the case is having enormous international relevance according to these irregularities detected.’ This is fabulously encouraging.
    Hope it leads to more nails in Pfizer’s coffin rather than nails in the coffins of people being given the vaccine again presently despite this warning.

    Which organisations in UK should be acting on this? Would they have been formally notified?

    Vaccinations for coronavirus
    Press release
    JCVI publishes advice on COVID-19 vaccines for autumn booster programme
    All of the available boosters provide good protection against severe illness from coronavirus (COVID-19).

    UK Health Security Agency
    15 August 2022

    The Joint Committee on Vaccination and Immunisation (JCVI) has published its advice on which vaccines should be used in this year’s autumn booster programme.

    All of the available boosters provide good protection against severe illness from COVID-19 and the Committee has emphasised that getting a booster in good time before the winter season is more important for those eligible than the type of vaccine that is received.

    The vaccines advised for use in the autumn booster programme are:

    For adults aged 18 years and above:

    Moderna mRNA (Spikevax) bivalent Omicron BA.1/Original ‘wild-type’ vaccine
    Moderna mRNA (Spikevax) Original ‘wild-type’ vaccine
    Pfizer-BioNTech mRNA (Comirnaty) Original ‘wild-type’ vaccine
    in exceptional circumstances, the Novavax Matrix-M adjuvanted wild-type vaccine (Nuvaxovid) may be used when no alternative clinically suitable UK-approved COVID-19 vaccine is available
    For people aged 12 to 17 years:

    Pfizer-BioNTech mRNA (Comirnaty) Original ‘wild-type’ vaccine
    For people aged 5 to 11 years:

    Pfizer-BioNTech mRNA (Comirnaty) Original ‘wild-type’ vaccine paediatric formulation
    ‘Bivalent’ vaccines have been developed by global manufacturers since the emergence and dominance of the Omicron variant. These vaccines contain two different antigens (substances that induce an immune response) based on two different COVID-19 strains, or variants. The original mRNA vaccines contain one antigen (monovalent), based on the original ‘wild-type’ strain.

    Studies indicate the Moderna bivalent vaccine produces a marginally higher immune response against some variants than the Moderna mRNA Original ‘wild-type’ vaccine. The clinical relevance of these small differences is uncertain.

    The committee will consider further bivalent vaccines for use in the programme as they are approved by the MHRA.

    In its latest advice the JCVI has stated that, where feasible, it would be preferable for a single type of booster vaccine to be offered throughout the duration of the autumn programme for simplicity of deployment.

    Professor Wei Shen Lim, Chair of COVID-19 immunisation on the JCVI, said:

    All of the available booster vaccines offer very good protection against severe illness from COVID-19. As more vaccines continue to be developed and approved, the JCVI will consider the benefits of including them in the UK programme.

    It is important that everyone who is eligible takes up a booster this autumn, whichever vaccine is on offer. This will increase your protection against being severely ill from COVID-19 as we move into winter.

    Dr Mary Ramsay, Head of Immunisation at UKHSA, said:

    Although cases of COVID-19 are relatively low at present, we are expecting to see the virus circulating more widely during the winter months.

    The booster is being offered to those at higher risk of severe illness and by taking up the booster vaccine this autumn, you will increase your protection ahead of the winter months, when respiratory viruses are typically at their peak.

    NHS England will confirm details on how and when eligible people can access the autumn booster vaccine in due course.

    Share this page
    Share onFacebook Share onTwitter
    Published 15 August 2022

  2. Congratulations must be conveyed to Augusto for his show of strength here. He stated his truth according to how he felt within himself. He shared the way he felt, had an explanation for his suffering – but then hit the wall of denial. How many times have we heard of this happening before?
    We can only imagine how many hours, days, even months Augusto has spent fighting his corner on this matter – but he hasn’t given up. That is the most important point of the whole story – he kept stirring, waiting for the truth to eventually appear. It seems that there is, now, a little more hope of the acceptance of Augusto’s “truth” in high places.
    I’m sure that Augusto would say that he’s held on to his principles here – that he’s worked so hard, not only for himself, but for ALL who have suffered both in trials and following vaccine jabs in the name of “Covid protection of others”.
    It is a total disgrace that Augusto has suffered in this way. It is mind-boggling to hear of the likely number of such cases worldwide. It is catastrophic that such vaccines are being promoted for use in ever-younger age groups.
    Augusto – please accept our thanks on behalf of all sufferers and we look forward to the next instalment of your story.

  3. “Likewise, it reports that the case is having enormous international relevance according to these irregularities detected.”

    Story of ‘disappeared patient’ goes public


    Dr Aseem Malhotra


    I’ve been informed from a very reliable source that the current Tory party plan on the unprecedented mRNA product harm data which THEY KNOW ABOUT is to try & bury it. We will not let this happen.The truth will out & the longer they delay action the greater the political damage.

    NHS should treat vaccine ‘injuries’ same way it does long Covid by introducing clinics to help affected patients, MP claims

    MP Sir Christopher Chope called for ‘Covid vaccine damage’ specialist clinics
    He said NHS should ‘take seriously’ helping few who’ve become unwell after jab
    He also said it should be easier for sufferers to access a £120,000 pay-out.

    ‘Child Abuse on a Massive Scale’: CDC Advisers Recommend Adding COVID Vaccines to Childhood Schedule

    The Centers for Disease Control and Prevention’s independent vaccine advisory committee today voted unanimously (15-0) to add COVID-19 vaccines for children as young as 6 months old to the new Child and Adolescent Immunization Schedules, which will be rolled out in February 2023.

    “This reckless action is final proof of the cynicism, corruption and capture of a once exemplary public health agency. ACIP members have again demonstrated that fealty to their pharma overlords eclipses any residual concerns they may harbor for child welfare or public health.

    “This is an act of child abuse on a massive scale.”

    Edward Dowd


    Yes but like all frauds I have seen they can’t stop and won’t stop until they are forced to stop. In corporate frauds we had regulators but in this fraud the regulators are in on it…interesting conundrum and only massive public outcry can stop this. This is a grind, there will be no movie story ending. No one coming to save you. We save ourselves. That’s why I focus on the marginal mind. There is a tipping point. Let’s accelerate that all of us collectively one mind at a time.

    Has the CDC Finally Gone Too Far?

    Mandating “Vaccines” for All Children is Suicide

    Pfizer raises price of Covid vaccine in US by four-fold

    A director told Reuters the new price for the jab will be around US$110-130 compared to US$30 currently

    Pfizer Inc (NYSE:PFE) is to put up the price of its Covid vaccine in the US by around four times, an executive for the pharma giant has confirmed.

    Angela Lukin told Reuters the new price for the jab will be around US$110-130 compared to US$30 currently, though it will still be available free of charge to people with private or US government healthcare insurance.

    “We are confident that the US price point of the COVID-19 vaccine reflects its overall cost-effectiveness and ensures the price will not be a barrier to access for patients,” Lukin said.

    Demand for Covid booster jabs has been falling recently and analysts said price hikes are needed for Pfizer and other vaccine makers such as Moderna and Novovax to hit financial targets this year.

    Reasons for the drop-off include a rise in Covid infections in those who have been vaccinated and new strains of the virus developing, with these leading people to question why they should have a jab.

    Having previously been forecast to be the same size as the flu market, analysts now suggest the market might only be a third of the size, though the vaccine companies disagree.

    John Trizzino, Novavax’s chief commercial officer, said that while vaccine fatigue and the belief the pandemic is over is affecting the number of people getting vaccinated, rising infection rates, hospitalisations and deaths will see that number pick up.

    Covid is a substantial earner for all three of the vaccine makers.


  4. Covid-Cradle…

    Are Covid vaccines for British babies on the way? Regulators are assessing data on Moderna’s jab for infants as young as six months

    EXCLUSIVE: Moderna submitted paperwork on baby jabs a few weeks ago
    UK regulator says it will only be approved if it meets strict safety standards
    But experts warn that the vaccine should not be rolled out to children en masse 
    International pressure is piling on Britain to approve Covid vaccines for babies  
    This week the EU’s medicines regulator approved Covid jabs for 6-month-olds

    Regulators may decide on whether Covid vaccines should be approved for British babies before Christmas. 

    The Medicines and Healthcare products Regulatory Agency (MHRA), which polices the safety of drugs used in the UK, told MailOnline it is currently reviewing data on Moderna’s vaccine.  

    The pharmaceutical firm has submitted evidence in the hope of getting its jab approved for children aged six months and older, as it is in the EU and US. 

    Only over-fives can currently get Covid vaccines in the UK.

    Any approval of jabs for babies would cause huge controversy. 

    British authorities have so far held out on approving jabs for infants despite massive pressure, due to concerns that the benefits do not outweigh any potential risks.

    Children rarely get seriously ill with Covid and the majority are thought to have already been infected.

    Experts said today that, even if approved, the jab must not be rolled out ‘en masse’ to healthy infants.

    Dr Laura Squire, the MHRA’s chief healthcare quality and access officer, revealed the regulator was processing an application from Moderna. 

    But she added the mRNA jab, which works in a similar way to Pfizer’s, would only be approved if it met strict safety and efficacy standards. 

    She said: ‘We have received an application from the company to extend the approval of Moderna to those aged six months to five years. 

    ‘No extension to the vaccine will be approved unless it meets our stringent standards of safety, quality and effectiveness.’

    Moderna’s jab application was submitted in mid-September, meaning it has already gone through weeks of analysis. 

    The MHRA declined to detail the timeframe for its expected decision.

    But it took health chiefs two months to consider the evidence before approving the first Covid jab in December 2020. 

    Moderna’s application is for its existing jab to be rolled out to other groups, rather than for a new drug. 

    Dr Squire also confirmed rival vaccine maker Pfizer has not yet applied to have its jab approved for use in the youngest children. 

    Professor David Livermore, a microbiologist at East Anglia University, said giving the jab to the very limited numbers of children with specific conditions might be wise. 

    He said: ‘The tiny minorities of children with severe underlying health problems may benefit from vaccination against Covid.’

    But he added that a large-scale jab campaign for children should be off the cards. 

    ‘There should be absolutely no question of mass vaccination of healthy children, for whom the benefits don’t outweigh the risks,’ the professor said. 

    ‘Over 80 per cent of children have now had Covid and have developed natural immunity. 

    ‘This lasts longer than vaccine-induced immunity and is broader in respect of covering variants. Vaccines offer nothing useful to this very large majority.’

    Professor Livermore said the risks of vaccine-related harm, while tiny, do not clearly outweigh the very minor benefits for the vast majority of children.  

    ‘This is acceptable for elderly vulnerable populations at risk from severe Covid,’ he said. 

    ‘It’s not acceptable for healthy children, who are at minuscule risk of developing severe Covid.’

    He added that he would like Britain to follow Denmark’s lead and stop vaccinating children against Covid unless recommended by a specialist paediatrician.

    While the MHRA may sign off the jab for use in children, a separate Government group, the Joint Committee on Vaccination and Immunisation, will decide under what circumstances it is dished out. 

    This could include a list of specific conditions that make children vulnerable to Covid, such as type 1 diabetes or sickle cell disease. 

    Covid vaccines for children in Briton have so far been incredibly unpopular.

    The latest Government data on vaccine uptake shows only 6 per cent of people aged between five to 11 in England have had two doses of a Covid vaccine.

    If Moderna’s jab was approved for use in UK babies, it would likely be an even smaller dose than the one offered to older children, itself reduced from the full vaccine dose offered to adults. 

    Lower doses are given to children to avoid complications, such as myocarditis — the rare condition that spooked health chiefs early on in the pandemic. 

    MailOnline attempted to contact Moderna for comment. 

    It comes after EU health chiefs approved both Moderna and Pfizer’s jabs for children as young as six months old.  

    Children in the age bracket whose parents want them to be jabbed with Pfizer’s will be offered a dose of three micrograms, under the European Medicines Agency (EMA) ruling.

    For comparison, adults in Britain get a dose ten times stronger. 

    Older children, who are allowed to be vaccinated in the UK, get given a dose of up to 10micrograms.

    Slightly stronger doses are recommended by the EMA for children given Moderna’s vaccine (25micrograms).

    This is half the dose given to older children in Britain, and a quarter of that approved for adults. 

    The EMA’s recommendations, which have already sparked concerns, will be sent to the European Commission for a final decision. 

    Scores of countries including the US, China and Israel, already offer vaccines to children under five, despite huge backlash over the moves.

    It sparked a huge debate over the merits of vaccinating children, given that their risk of falling seriously ill with the virus is tiny. 

    The mNRA jabs, made by Pfizer and Moderna, have been linked to a rare chance of myocarditis.

    Data has shown the risk of the condition — which is usually mild— is highest in younger people, especially boys.

    Up to September 28 this year, there have been 83 cases of suspected myocarditis or pericarditis (a similar heart inflammation) in under-18s who received a Covid vaccine in the UK. 

    All reported cases were youths who received the Pfizer jab, not Moderna’s. 

    Seven fatalities have been reported to the MHRA for children who received a Covid vaccine in the UK.

    Reports of a fatality only indicate a suspicion the death was linked to the vaccine, not conclusive proof.  

  5. “Not to diss the current mRNA vaccines, but because we owe it to the population …

    FDA’s vaccines chief sees possibility of more Covid boosters — sooner than he’d like

    Peter Marks, who leads the Food and Drug Administration’s vaccines operation, is still losing sleep over Covid.

    Yes, vaccines for all age groups have been authorized or approved. Yes, an updated vaccine is now available. And, yes, multiple products are in use and hundreds of millions of doses have been given in this country.

    But Marks said there are other issues that weigh on him.
    Chief among them is the fact that, given the rate at which SARS-CoV-2 viruses mutate, Marks thinks it’s conceivable that the booster shot people are getting now may not be the last some will need for the coming year.

    “I would be lying to you if [I said] it doesn’t keep me up at night worrying that there is a certain chance that we may have to deploy another booster — at least for a portion of the population, perhaps older individuals — before next September, October,” Marks told STAT.

    “I’m not saying that’s what’s going to happen, but it’s what keeps me up at night, because we see how fast this virus is evolving.”

    The messenger RNA vaccines most commonly used in the United States — the products made by Moderna and the Pfizer-BioNTech partnership — can easily be tweaked to update the strains of the virus they target. The speed with which these vaccines can be adapted and produced has revolutionized pandemic response.

    But the vaccines as currently designed do not offer long-term protection against infection. Severe disease, hospitalization, and death, yes. But the duration of protection against contracting Covid is short-lived — which could lead to a vaccination cadence that is impractical to try to maintain.

    Marks acknowledged this worries him.

    “It does,” he said, noting this problem is leading to pressure on the mRNA manufacturers to see if they can improve the durability of their vaccines. “Because there are probably things that can be done to optimize sequences and optimize constructs that would hopefully lead to better mRNA vaccines.”

    But the long-term answer, Marks said, doesn’t just rest with vaccines made using mRNA.

    “We need to look at other other types of vaccines. And there are those out there that might provide more durable immunity,” he said.

    “I would love to see us have a very ecumenical look over all of the available vaccines and all of the vaccines in development to try to see what’s best moving forward,” Marks said. “Not to diss the current mRNA vaccines, but because we owe it to the population to see what might provide the greatest breadth, depth, and duration of immunity against Covid-19.”

    Some of this work will take time, especially if federal government funding for next-generation vaccines does not come through. (And there’s currently no indication it will.)

    With each successive booster that has been approved, the percentage of people who’ve gotten one has dropped. A bivalent booster, which targets both the original strain of SARS-2 and an Omicron variant, has been available since early September.

    To date only 19.4 million doses have been administered. The public’s Covid fatigue could disincentivize vaccine manufacturers from trying to produce better, longer-lasting vaccines, Marks suggested.

    In the near term, he said he’d be happy if we could get to the point where an annual shot would suffice. “I would consider it a success at this point,” he said.

    For the time being, Marks believes Covid vaccines are going to need to be updated on a regular basis, along the lines of what is done with flu vaccines.
    Twice a year the World Health Organization convenes influenza experts to study the flu viruses that are circulating and choose strains for the Northern and Southern Hemisphere. The goal is to tweak the vaccine formulas so they target the strains that will be causing the most disease several months later. It is a hit-and-miss — more miss — endeavor.

    The expert panel that advises the WHO on Covid vaccines has suggested eschewing that approach with SARS-2. Instead, the group, known as the Technical Advisory Group on Covid-19 Vaccine Composition, recommended updating Covid vaccines with a strain that is genetically highly distinct from the original strain, to broaden the immune system’s experience with SARS-2 viruses, choosing a version of Omicron that is no longer spreading.

    When the FDA told Covid vaccine manufacturers what it wanted in updated vaccines, it did not follow the WHO advice to the letter, opting for a version of Omicron that matched the dominant version of the virus at the time the decision was made. (The virus’ rapid evolution means that strain is already being superseded by others.)

    Marks said he believes trying to match the virus will be important for the next couple of years.

    “What I can say is in … the short term, the next year or two, we are pursuing a flu-like chase-the-variant model,” he said.

    Another near-term change Marks foresees include moving to a bivalent primary vaccine, so that anyone who is being vaccinated — whether they’re getting their first shot or their fifth — will get vaccine targeting the original strain and an Omicron strain. At present only booster shots are bivalent.

    The FDA is waiting for additional data before making this move, said Marks. “Once we have those data — which we expect in the next few months — we will go to a public advisory committee meeting, probably in the first part of next year to have a discussion about moving things over to the bivalent … primary series.”

    In the meantime, Marks is hoping to see an improvement in the uptake of Covid vaccine — primary series and boosters — for young children, where the acceptance rates remain very low. “It is kind of disappointing that a public health measure that is so clearly beneficial has been way under-utilized,” he said.


  6. “Covid has shined a light” …

    Brook Jackson

    “It doesn’t matter if we broke every clinical trial in the book”

    Brook Jackson 

    Ventavia Research Group, defendants in a Federal FCA lawsuit alleging clinical trial misconduct/fraud just scored their 3rd contract with Moderna. There is potential for a crisis of public health & safety if Ventavia is permitted to continue participating in clinical trials.

    Brook Jackson 

    Just watched this interview with FDA advisory board member, Kim Witczak. Please SHARE COVID shined a light on so much corruption w/in pharma, govts & public health agencies. Regardless of whether you realized this before or now, what matters is how we come together to stop it.


    Kim Witczak once sued Pfizer and WON. How many people can say that? Highly recommend this recent interview…

    “Covid has shined a light” …

    Court Orders Depositions of Top Biden Officials in Missouri AG’s Case

    said Attorney General Schmitt. “It is high time we shine a light on this censorship enterprise and force these officials to come clean to the American people, and this ruling will allow us to do just that. We’ll keep pressing for the truth.”

    allowing Missouri and Louisiana to depose top-ranking officials in the federal government under oath.

    “It is high time we shine a light ..

  7. Dr. Robert M. Califf
    Oct 18

    Dr. Tabak has an important message. We need to get the message to all clinicians to talk with their patients and to all people that the vaccine works!

    Lawrence A. Tabak
    Oct 18

    Have you gotten your updated #COVID19 #booster yet? If not, some new data on #vaccines in #veterans might give you some needed encouragement. #NIH

    Happy Holidays…

    On October 20, 2022, the Center for Disease Control claimed the benefits outweigh the risks and voted YES to approve to add the COVID-19 vaccines to the children’s immunization schedule.

    No pharmaceutical product is 100% safe. There are risks with all drugs and vaccines. The important point to note is that if your child is harmed by the COVID vaccine there is no support for your child. The drug companies are not liable, the government is not liable if something goes wrong.

    Horowitz: The man who holds the key to bringing down the Pfizer pfraud

    Get the inside story from Augusto Roux – intro — around 20 min. in

    On today’s special show, we are joined by Augusto Roux, a criminal law attorney from Buenos Aires who participated in the largest Pfizer clinical trial site. He shares his riveting story of how he was immediately injured after the second dose and suffers from pericarditis and liver damage. Instead of recording his injury in the clinical trial data, the company blamed it on COVID (even though he tested negative) and diagnosed him with anxiety. He shows how Pfizer committed fraud and violations of human rights every step of the way. He also discovered how the company covered up two deaths at the same trial site and how hospital officials told him they treated numerous people with severe injuries in the trial. None of them were recorded. We need a Nuremberg trial, and Augusto might have the evidence to conduct it!

    Polack sends a ‘love’ letter, bogus psychiatric diagnosis and other violating bombs – ”Polack is very aggressive with me”, “he’s like a witcher”…

    The Cover-Up, the disappeared…

  8. Pfizer’s friends (snippets)

    Pfizer has partnered with NHS England, NICE and the UK government to pilot a world-first innovative reimbursement model for antimicrobials.
    Cross-industry collaboration is crucial to tackle AMR head on, with the same urgency as our response to COVID-19. Pfizer is a proud member of the AMR Industry Alliance, a coalition of over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations.5 Alliance members are currently investigating 93 products or technologies covering ‘traditional’ antibiotics and antifungals, vaccines, diagnostic platforms, assays and non-traditional or other products.
    NEWS & FEATURED STORIES/ Hope On The Horizon: Why It’s Not Too Late For Antimicrobials
    Toby Cousens
    Hospital Lead, Pfizer UK

    Developing new antimicrobials requires huge financial investment – in excess of $1 billion3 – and once approved are often used sparingly to support good stewardship. This creates a challenging dichotomy: needing to preserve public health, while making it difficult to recover the high costs associated with antimicrobial development. To solve this, we must re-think how we incentivise R&D.

    Cross-industry collaboration is crucial to tackle AMR head on, with the same urgency as our response to COVID-19. Pfizer is a proud member of the AMR Industry Alliance, a coalition of over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations.5 Alliance members are currently investigating 93 products or technologies covering ‘traditional’ antibiotics and antifungals, vaccines, diagnostic platforms, assays and non-traditional or other products.

    RESPONSIBILITY/ Transparency
    We know that transparency is essential to building and maintaining confidence in us and in our medicines. We want people to know, and understand, what we do and how we do it.

    Our business is regulated by the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry which has detailed requirements to ensure its member companies operate in a responsible, ethical and professional manner. The Code includes requirements for how we may work with healthcare professionals, healthcare organisations and patient organisations and in recent years it has introduced new requirements for greater transparency in these areas.

    We strongly support the work the European Federation of Pharmaceutical Industries and Associations (EFPIA) and ABPI have done to move towards greater transparency across the pharmaceutical industry.

Leave a Reply